Literature DB >> 22887781

Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia.

Lilia Kraoua1, Hubert Journel, Philippe Bonnet, Jeanne Amiel, Nathalie Pouvreau, Clarisse Baumann, Alain Verloes, Hélène Cavé.   

Abstract

Recently, germline mutations of NRAS have been shown to be associated with Noonan syndrome (NS), a relatively common developmental disorder characterized by short stature, congenital heart disease, and distinctive facial features. We report on the mutational analysis of NRAS in a cohort of 125 French patients with NS and no known mutation for PTPN11, KRAS, SOS1, MEK1, MEK2, RAF1, BRAF, and SHOC2. The c.179G>A (p.G60E) mutation was identified in two patients with typical NS, confirming that NRAS germline mutations are a rare cause of this syndrome. We also screened our cohort of 95 patients with juvenile myelomonocytic leukemia (JMML). Among 17 patients with NRAS-mutated JMML, none had clinical features suggestive of NS. None of the 11 JMML patients for which germline DNA was available had a constitutional NRAS mutation.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22887781     DOI: 10.1002/ajmg.a.35513

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  10 in total

1.  Genotype and phenotype spectrum of NRAS germline variants.

Authors:  Franziska Altmüller; Christina Lissewski; Debora Bertola; Elisabetta Flex; Zornitza Stark; Stephanie Spranger; Gareth Baynam; Michelle Buscarilli; Sarah Dyack; Jane Gillis; Helger G Yntema; Francesca Pantaleoni; Rosa LE van Loon; Sara MacKay; Kym Mina; Ina Schanze; Tiong Yang Tan; Maie Walsh; Susan M White; Marena R Niewisch; Sixto García-Miñaúr; Diego Plaza; Mohammad Reza Ahmadian; Hélène Cavé; Marco Tartaglia; Martin Zenker
Journal:  Eur J Hum Genet       Date:  2017-05-03       Impact factor: 4.246

Review 2.  Pediatric Neoplasms Presenting with Monocytosis.

Authors:  Jacob R Greenmyer; Mira Kohorst
Journal:  Curr Hematol Malig Rep       Date:  2021-02-25       Impact factor: 3.952

Review 3.  Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Authors:  Michael W N Deininger; Jeffrey W Tyner; Eric Solary
Journal:  Nat Rev Cancer       Date:  2017-06-23       Impact factor: 60.716

4.  An integrative computational analysis provides evidence for FBN1-associated network deregulation in trisomy 21.

Authors:  Mireia Vilardell; Sergi Civit; Ralf Herwig
Journal:  Biol Open       Date:  2013-06-20       Impact factor: 2.422

Review 5.  Mutation in NRAS in familial Noonan syndrome--case report and review of the literature.

Authors:  Sara Ekvall; Maria Wilbe; Jovanna Dahlgren; Eric Legius; Arie van Haeringen; Otto Westphal; Göran Annerén; Marie-Louise Bondeson
Journal:  BMC Med Genet       Date:  2015-10-14       Impact factor: 2.103

Review 6.  Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia.

Authors:  Claudia Fiñana; Noel Gómez-Molina; Sandra Alonso-Moreno; Laura Belver
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639

7.  Integrated in silico MS-based phosphoproteomics and network enrichment analysis of RASopathy proteins.

Authors:  Javier-Fernando Montero-Bullón; Óscar González-Velasco; María Isidoro-García; Jesus Lacal
Journal:  Orphanet J Rare Dis       Date:  2021-07-06       Impact factor: 4.123

Review 8.  Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation.

Authors:  Christopher C Dvorak; Mignon L Loh
Journal:  Front Pediatr       Date:  2014-03-28       Impact factor: 3.418

9.  1p13.2 deletion displays clinical features overlapping Noonan syndrome, likely related to NRAS gene haploinsufficiency.

Authors:  Natália Duarte Linhares; Maíra Cristina Menezes Freire; Raony Guimarães Corrêa do Carmo Lisboa Cardenas; Heloisa Barbosa Pena; Katherine Lachlan; Bruno Dallapiccola; Carlos Bacino; Bruno Delobel; Paul James; Ann-Charlotte Thuresson; Göran Annerén; Sérgio D J Pena
Journal:  Genet Mol Biol       Date:  2016-08-04       Impact factor: 1.771

10.  Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.

Authors:  Natacha Bohin; Tiffany Wen; Qing Li; Victor Ng; Jeffrey Magee; Shann-Ching Chen; Kevin Shannon; Sean J Morrison
Journal:  Nature       Date:  2013-11-27       Impact factor: 49.962

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.